Lauren Hekman, Eva Napierkowski, Natalie C Hartman, Jeffrey L Ellis, Robert H Wagner, Davide Bova, Maria M Picken, Robert C Flanigan
{"title":"Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment.","authors":"Lauren Hekman, Eva Napierkowski, Natalie C Hartman, Jeffrey L Ellis, Robert H Wagner, Davide Bova, Maria M Picken, Robert C Flanigan","doi":"10.1155/2023/1458175","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA PET has not been studied as a potential tool for hepatocellular carcinoma (HCC). We describe the case of a 76-year-old male with a rising prostate-specific antigen (PSA) after definitive prostate cancer treatment and no prior liver pathology who was incidentally found to have HCC on 18F-PSMA PET.</p>","PeriodicalId":9600,"journal":{"name":"Case Reports in Surgery","volume":"2023 ","pages":"1458175"},"PeriodicalIF":0.6000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10733019/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/1458175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA PET has not been studied as a potential tool for hepatocellular carcinoma (HCC). We describe the case of a 76-year-old male with a rising prostate-specific antigen (PSA) after definitive prostate cancer treatment and no prior liver pathology who was incidentally found to have HCC on 18F-PSMA PET.
前列腺特异性膜抗原正电子发射断层扫描（PSMA PET）已获美国食品和药物管理局（FDA）批准，用于在生化复发的情况下鉴别前列腺癌，但也可鉴别其他恶性肿瘤。18F-PSMA PET 作为一种潜在的肝细胞癌（HCC）检测工具尚未得到研究。我们描述了这样一个病例：一名 76 岁的男性在前列腺癌明确治疗后前列腺特异性抗原 (PSA) 不断升高，但之前未进行过肝脏病理检查，18F-PSMA PET 意外发现他患有肝细胞癌。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
